Related Experiment Video
Updated: Jul 15, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Current strategies with high-dose tirofiban
Debabrata Mukherjee1, Marco Roffi
1Gill Heart Institute, University of Kentucky, 326 Wethington Bldg, 900 S. Limestone, Lexington, Kentucky 40436-0200, USA. Mukherjee@uky.edu
Expert Opinion on Drug Metabolism & Toxicology
|April 13, 2007
Summary
High-bolus dose tirofiban may offer a cost-effective alternative to abciximab for reducing cardiovascular events. Further research is needed to confirm its efficacy and safety in percutaneous coronary interventions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Glycoprotein (GP) IIb/IIIa receptor antagonists are crucial for managing cardiovascular events post-percutaneous coronary interventions and in acute coronary syndromes.
- Abciximab, tirofiban, and eptifibatide are available intravenous GP IIb/IIIa inhibitors.
Purpose of the Study:
- To evaluate the efficacy and safety of a high-bolus dose of tirofiban compared to abciximab in patients undergoing percutaneous coronary intervention.
- To determine if high-bolus dose tirofiban is a cost-effective alternative to abciximab.
Main Methods:
- A head-to-head comparison of tirofiban (10-microg/kg bolus followed by 0.15-microg/kg/min infusion) versus abciximab was initially conducted.
- Subsequently, a high-bolus dose of tirofiban (25 microg/kg bolus) followed by standard infusion was tested.
Main Results:
- Low-dose tirofiban was found to be inferior to abciximab in patients undergoing percutaneous coronary intervention, likely due to insufficient platelet inhibition.
- Evidence suggests that high-bolus dose tirofiban may achieve comparable efficacy and safety to abciximab.
Conclusions:
- High-bolus dose tirofiban presents a potentially appealing and cost-effective alternative to abciximab.
- Further investigation with longer follow-up and greater statistical power is warranted to confirm these findings.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...